<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3BD17EA-7310-43F3-A920-46864ED0A1B5"><gtr:id>D3BD17EA-7310-43F3-A920-46864ED0A1B5</gtr:id><gtr:name>Proteome Sciences plc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B1C8126F-74A6-4C31-97BA-D521464418A9"><gtr:id>B1C8126F-74A6-4C31-97BA-D521464418A9</gtr:id><gtr:name>U.S. Department of Agriculture USDA</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3BD17EA-7310-43F3-A920-46864ED0A1B5"><gtr:id>D3BD17EA-7310-43F3-A920-46864ED0A1B5</gtr:id><gtr:name>Proteome Sciences plc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B1C8126F-74A6-4C31-97BA-D521464418A9"><gtr:id>B1C8126F-74A6-4C31-97BA-D521464418A9</gtr:id><gtr:name>U.S. Department of Agriculture USDA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1204FBCF-E8B8-42ED-B9DB-D061FB77ACF6"><gtr:id>1204FBCF-E8B8-42ED-B9DB-D061FB77ACF6</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>Jackson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U123170362"><gtr:id>3F4D11A1-161D-4638-AF07-CE225D73C461</gtr:id><gtr:title>Molecular diagnostic strategies in prion disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U123170362</gtr:grantReference><gtr:abstractText>The majority of the UK population and a lesser proportion of continental European and the rest of the world have been exposed to BSE contaminated foods and this has resulted in the new disease vCJD. Although the number of patients remains small, the number of people infected but without any signs of illness is unknown and could be very large. The time from being infected to showing signs of the disease can be very long and maybe up to 50 years. During this period there is a risk of spreading the disease through the contamination of medical and dental instruments; the use of contaminated blood for transfusion and the transplantation of infected organs such as kidneys. All of these dangers can be avoided if simply tests are developed that can detect CJD. Accurate tests that work on blood samples would allow the testing of everyone who donated blood for transfusions and the testing of anyone due to have surgery.||After infection with BSE there is a characteristic change that occurs to one of the bodys normal proteins in people who have the disease and the detection of this altered protein or prion can be used to show someone has CJD. Unfortunately the amounts of prion are very low in blood and are difficult to tell apart from the large amounts of the normal protein that are always present in both healthy and infected people.||We are trying different ways of detecting this rare altered protein. One approach is to copy the way the prion reproduces itself in the human body during disease. This will allow us to amplify the very small amounts of prion in blood samples up into large amounts that can be easily detected using ordinary laboratory tests.||As an alternative to amplification we are also finding ways to concentrate prions. If we can find ways to extract all the prions from a test-tube of blood this will make their detection much easier. We have found ways to extract prions from blood and detect them sufficiently well to distinguish infected blood from normal samples. We are trying to understand how prions copy themselves in replication reactions and aim to use concentration and replication to make prions in blood easily detectable.</gtr:abstractText><gtr:technicalSummary>The emergence of vCJD, and the experimental confirmation that it is caused by the same prion strain as bovine spongiform encephalopathy (BSE) has dramatically highlighted the need for ante-mortem diagnostic tests for prion disease and reliable methods for the destruction of prion infectivity. The extremely prolonged and variable incubation periods of these diseases, particularly when crossing a species barrier, and the demonstration of a discrete number of as yet uncharacterised genetic loci with a major effect on incubation periods, means that it will be some years before the parameters of any human epidemic can be predicted with confidence. In the meantime, we are faced with the possibility that significant numbers in the population may be incubating this disease and infect others via blood transfusion, blood products, tissue and organ transplantation and other iatrogenic routes. The recent demonstration of sub-clinical carrier states of prion infection in animal models is also relevant to public health, both with respect to prion zoonoses and iatrogenic transmission of human prions. The immediate solution to many of these problems is to provide a sensitive blood-based pre-symptomatic diagnostic test for prion infection.||This programme aims to investigate basic aspects of prion biology that are directly relevant to methods for blood-based diagnostic testing, and to couple such basic research with translational research such as immunoassay optimisation and proteomics screening in order to provide a co-ordinated approach to ante-mortem diagnostics.||Key projects within the research programme are aimed at developing methods for the amplification of PrPSc and infectivity from patient blood samples. The nascent technology of PMCA (Protein Misfolding by Cyclic Amplification) has been investigated as a means to replicate PrPSc to detectable levels from normal blood samples spiked with high dilutions of infected brain homogenate and from blood sampled from mice in the pre-clinical stages of experimental prion disease. We aim to dissect these reactions to define and understand the molecular events that constitute prion replication and identify what components of PMCA substrate (currently treated brain homogenate) are crucial for efficient prion replication. In parallel simplified amplification reactions in which recombinant PrP can be induced to fibrilise are being studied. Such reactions can be seeded and accelerated with preformed fibrils of recombinant PrP. These reactions can be also be catalysed by the addition of infected tissue homogenates or blood. We are investigated means to enhance the speed and sensitivity of such assays and aim to combine knowledge gained from understanding PMCA with recombinant PrP to enable purely synthetic, in vitro prion replication.||Separate projects are underway to increase the sensitivity of PrPSc detection in immunoassays by developing new methods for the capture and enrichment of disease-associated PrP prior to assay and by improving sandwich ELISA formats by screening a panel of over 80 monoclonal anti-PrP antibodies for optimum pairings. We have made considerable progress and extended the sensitivity of immunodetection to levels greater than the sensitivity afforded by rodent bioassays, being able to detect infected vCJD brain homogenate at a dilution of 1010. Application of this methodology to both endogenous rodent and patient blood samples has confirmed that we are able to differentiate infected blood from control samples.</gtr:technicalSummary><gtr:fund><gtr:end>2017-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>7377060</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>ROC</gtr:description><gtr:id>1160EA9B-C4C9-4E96-8E98-9FBA43BAB325</gtr:id><gtr:impact>19781641</gtr:impact><gtr:outcomeId>429171B39DD-1</gtr:outcomeId><gtr:partnerContribution>Broadening of knowledge.</gtr:partnerContribution><gtr:piContribution>Expertise in protein biochemistry, enzymology and molecular biology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Proteome Sciences plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Proteomics screening</gtr:description><gtr:id>FF54B663-2C33-44FC-885B-935477701F7F</gtr:id><gtr:impact>Acquisition of knowledge. 17552550</gtr:impact><gtr:outcomeId>83AECA24985-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise and knowledge. Performing analysis on the company's premises at the company's expense with company staff.</gtr:partnerContribution><gtr:piContribution>Provision of samples and directing research programmes to identify surrogate markers of disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>U.S. Department of Agriculture USDA</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Adaptation of prion blood test to CWD screening</gtr:description><gtr:id>66802497-3F73-4F90-9EB3-07636D50EB2E</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>5457627a7515c3.99182326-1</gtr:outcomeId><gtr:partnerContribution>Expertise, samples and personnel.</gtr:partnerContribution><gtr:piContribution>Expertise, know-how and proprietary reagents.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Proteasome inhibition and prion disease.</gtr:description><gtr:id>DC5FB2AB-13A9-40D6-81AD-C58939FF49BB</gtr:id><gtr:impact>17466621</gtr:impact><gtr:outcomeId>7CA775BE0D2-1</gtr:outcomeId><gtr:partnerContribution>Increased knowledge.</gtr:partnerContribution><gtr:piContribution>Provided expertise in prion biology, protein biochemisty and enzymology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infectious Disease &amp; Epidemiology</gtr:department><gtr:description>Role of PrP in the immune system.</gtr:description><gtr:id>4AA96767-6168-4CCF-95E8-98CB2EF958A5</gtr:id><gtr:impact>19204074 18462346 17086102 16968391</gtr:impact><gtr:outcomeId>0D32821670B-1</gtr:outcomeId><gtr:partnerContribution>Provided expertise and knowledge of immunology and laboratory techniques associated with this field.</gtr:partnerContribution><gtr:piContribution>Expertise and knowledge of prion biology and disease. Laboratory space and supervision for a PhD student</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>The role of SOD misfolding in the aetiology of ALS</gtr:description><gtr:id>9DE4281F-63EC-4899-8452-CDB5474FA32D</gtr:id><gtr:impact>Peer reviewed publications (PubMed IDs : 20498711, 20221404, 20382740)</gtr:impact><gtr:outcomeId>5457674e1f8f72.71834524-1</gtr:outcomeId><gtr:partnerContribution>Expertise, know-how, samples and personnel.</gtr:partnerContribution><gtr:piContribution>Expertise, know-how, laboratory space, equipment and reagents.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>NHSBT London Regional Transfusion Committee Business Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BF729FD9-8810-4E3B-A070-4BADDF75CE76</gtr:id><gtr:impact>Presentation on the risks and risk reduction strategies for the iatrogenic transmission of prion disease through blood and blood products.

NHSBT London Regional Transfusion Committee are now interested in having regular presentations as part of their CPD programme.</gtr:impact><gtr:outcomeId>coGNBHrve16</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6DDB562E-688B-4488-9C7B-917D5858C301</gtr:id><gtr:impact>Several national and international newpapers and magazines used my comments in the construction or articles reporting the publication of prevalence estimates for vCJD.

The MRC was quotee in several national and international newpaers and magazines.</gtr:impact><gtr:outcomeId>LoLsd7jWshW</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-24525584,  http://www.dailymail.co.uk/health/article-2461354/Mad-cow-disease-One-2-000-people-UK-carry-abnormal-proteins-linked-vCJD.html?ITO=1490&amp;ns_mchannel=rss&amp;ns_campaign=1490 , http://news.sky.com/story/1154928/cjd-st</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interviews to discuss the possibility of a urine test for CJD.</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0A83512C-2E50-4342-AC6E-20D9BC4BE752</gtr:id><gtr:impact>Media interviews to discuss the possibility of a urine test for CJD.</gtr:impact><gtr:outcomeId>58c6b1464e9647.43905170</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-37541550</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at patient open day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D3222B54-7B41-4551-BBEB-B8F9C6FB2FC0</gtr:id><gtr:impact>A mixed audience of patients, relatives, carers, health professionals and politicians attended an open at the Prion Unit and National Prion Clinic. A presentation of our work sparked several qauestions and discussions.

Patients and carers were pleased to here of our progress.</gtr:impact><gtr:outcomeId>FVRpq5gRyvq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PDA Virus and TSE Safety Forum, Caiscais, Portugal.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7F816039-03EF-4473-B83F-7C3C087D3E0A</gtr:id><gtr:impact>Parenteral Drug Association, Virus and TSE Safety Forum.

http://10.5731/pdajpst.2016.006569</gtr:impact><gtr:outcomeId>58c6b090358e93.22867542</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Blood Test Press Communications</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D11BE151-8125-4EAE-95BB-07E18824AB4F</gtr:id><gtr:impact>Answered questions from the media to provide quotations and accurate information for publication.

Public communication of the MRC's research and achievements.</gtr:impact><gtr:outcomeId>nA6yfb5dDgK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media statement relating the identification of vCJD in an MV heterozygote.</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2EE80ADA-C33D-481C-B991-650DA7018BA8</gtr:id><gtr:impact>Statement made for release to the media. This resulted in further enquires from the media and reporting in The Times and New Scientist.</gtr:impact><gtr:outcomeId>58c6b20fc64355.50285411</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.sciencemediacentre.org/expert-reaction-to-first-reported-case-of-variant-creutzfeldt-jakob-disease-in-a-patient-with-mv-genotype/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CSC Decontamination lecture.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1443705B-DCD3-4DB3-A3D8-0439CF8DE3FB</gtr:id><gtr:impact>Oral presentation at a trade conference for professionals working in the area of surgical instrument decontamination and sterilisation. (CSC Annual Conference, Manchester 2007)

Press coverage of the event and the presentation.</gtr:impact><gtr:outcomeId>E063452C0F1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>98000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT Development Gap Funding</gtr:description><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>8BD4E4EF-F717-4817-AFD5-09CBE4CE48C5</gtr:id><gtr:outcomeId>AAE5CB75C7D0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Additional ad hoc funding for blood test validation</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>708A16A0-424A-4211-981B-25A49CAA1C2F</gtr:id><gtr:outcomeId>BpJGg1GEwgB</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>232535</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>JPND DEMTEST</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9D954637-6201-4346-89E0-C80CBA5A64F9</gtr:id><gtr:outcomeId>EDErb7X6K9i</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A novel assay that is the basis for a blood test to detect infection with vCJD.</gtr:description><gtr:grantRef>MC_U123170362</gtr:grantRef><gtr:id>A188CA76-A3A6-4D06-832E-F55CC0207C24</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>PjoRC4GPR24</gtr:outcomeId><gtr:patentId>WO2012035296</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>A blood test for vCJD</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the CJD Experts Group, European Medicines Agency</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>78485AA8-1BF5-4023-A6C2-CEB4BA6C573D</gtr:id><gtr:outcomeId>58c6b2f2864960.04513811</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Commons Science and Technology Report on vCJD</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>449E8345-1109-4C5E-BBD0-850C6514300C</gtr:id><gtr:outcomeId>54576febc86728.33705231</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NATA</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6D4EA564-285F-4282-BE80-9A580B3ECB89</gtr:id><gtr:outcomeId>46EB27BB4D0</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>UK National Clinical Human Embryonic Stem Cell Forum</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8B2CE9EE-6656-4F12-894B-36140CC969C5</gtr:id><gtr:outcomeId>QpUSupiWgsc</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Blood test for the presence of prion infection. This has completed initial development and is currently in the final stages of clinical evaluation and adoption by UCLH NHS Trust. Further development is wholly funded by the MRC.</gtr:description><gtr:id>BB6D389A-9495-4CD8-A9FB-D9BDBBE2FF1E</gtr:id><gtr:impact>This test has been used in the clinical care of around 250 patients. 
The high specificity of the test has allowed consideration of a UK wide prevalence study for vCJD infection in blood.</gtr:impact><gtr:outcomeId>R2NwPgzHbm4</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Clinical DDA</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>D-Gen</gtr:companyName><gtr:description>D-Gen was formed as an Imperial College spin-out company to commercialise relevant research emanating from the work of Professor John Collinge's team at the MRC Prion Unit (now based at the Institute of Neurology, University College London).; http://www.d-gen.co.uk/</gtr:description><gtr:id>D8F66F97-84C4-4E66-B833-58C437B098FB</gtr:id><gtr:impact>D-Gen is a private research-based bio-medical Company which innovates in the field of prion-related disease by identifying, developing and exploiting proprietary diagnostic and therapeutic targets and technologies. D-Gen founders include the MRC, Imperial College, the Wellcome Trust and the University of Bristol, in addition to founder inventors.</gtr:impact><gtr:outcomeId>EAEBF2599DD</gtr:outcomeId><gtr:url>http://www.d-gen.co.uk/</gtr:url></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>6EE5D5B9-CA65-4FD6-B725-29F2CEE42ECA</gtr:id><gtr:title>Codon 129 polymorphism of the human prion protein influences the kinetics of amyloid formation.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>423A7B05BC8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD669D2E-8F34-4727-8CB6-558643F714C6</gtr:id><gtr:title>A reassessment of copper(II) binding in the full-length prion protein.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2b398fefefb405c70b3a85a98965243"><gtr:id>c2b398fefefb405c70b3a85a98965243</gtr:id><gtr:otherNames>Wells MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>L8ePNN9E3Uj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05D62070-3253-4C33-AECC-D923875E4525</gtr:id><gtr:title>Inhibition of proteinase K activity by copper(II) ions.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3c0d274c9d3ef761e989e7a43f3c0a"><gtr:id>8b3c0d274c9d3ef761e989e7a43f3c0a</gtr:id><gtr:otherNames>Stone LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>jC2gDgsVMBq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F5E5BEE-037F-462B-81E0-FC88E2F4D5B2</gtr:id><gtr:title>Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7ddc22e04c6f9bc94f5ca63e2f1de34"><gtr:id>c7ddc22e04c6f9bc94f5ca63e2f1de34</gtr:id><gtr:otherNames>Thompson AGB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5a9d2bd44d9ce0.17094614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E8E5DF7-C51B-4AA2-B44F-E3823DF46496</gtr:id><gtr:title>A highly specific blood test for vCJD.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d35fcc5cee51bf10673b89f590a94d4a"><gtr:id>d35fcc5cee51bf10673b89f590a94d4a</gtr:id><gtr:otherNames>Jackson GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>54575d4b2f1709.53902980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CBE35C7-09FC-409F-B6F8-686D53A12455</gtr:id><gtr:title>Modification of superoxide dismutase 1 (SOD1) properties by a GFP tag--implications for research into amyotrophic lateral sclerosis (ALS).</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abc3f233f373ed02719f6b6d5e5fa937"><gtr:id>abc3f233f373ed02719f6b6d5e5fa937</gtr:id><gtr:otherNames>Stevens JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>TfeL8XtN5pZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>215199E7-1777-4CB0-926D-84A3BFBF245E</gtr:id><gtr:title>Discrimination between prion-infected and normal blood samples by protein misfolding cyclic amplification.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e073b120372c44bd19d0a6219bb4623"><gtr:id>3e073b120372c44bd19d0a6219bb4623</gtr:id><gtr:otherNames>Tattum MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>ezzHiGg2Xwu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B6A2BE1-2079-4777-8980-2542FD11D9EF</gtr:id><gtr:title>The role of the cellular prion protein in the immune system.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f2054f5020a7ad7e4cf404fcb230223"><gtr:id>5f2054f5020a7ad7e4cf404fcb230223</gtr:id><gtr:otherNames>Isaacs JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>NF1iLh91LiB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB847993-DF6C-4978-A4D8-C6B90FB14547</gtr:id><gtr:title>Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06ab6093040e00d0d66b52b73de3246"><gtr:id>a06ab6093040e00d0d66b52b73de3246</gtr:id><gtr:otherNames>Dalrymple A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>77292BB3C7B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>458B0357-6C18-485E-B4FA-B721BB45819D</gtr:id><gtr:title>PRNP allelic series from 19 years of prion protein gene sequencing at the MRC Prion Unit.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cfdf106876171606d0edeedb5461e8f"><gtr:id>5cfdf106876171606d0edeedb5461e8f</gtr:id><gtr:otherNames>Beck JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>NBQSxNJY9we</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2B3FDB4-18C6-46C9-AC8C-E13DAF272951</gtr:id><gtr:title>Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55f56b55a8edaec06737db2514e2fe96"><gtr:id>55f56b55a8edaec06737db2514e2fe96</gtr:id><gtr:otherNames>Sawyer EB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56a8a7b82cce00.36038341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3058B55-FFFB-4213-83AD-04B27748D784</gtr:id><gtr:title>Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7b7e2fe78d5e2742820eea3aa14ddd"><gtr:id>5d7b7e2fe78d5e2742820eea3aa14ddd</gtr:id><gtr:otherNames>Edgeworth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>TFUeDWXnwSj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C184AEFF-672F-4942-BAC7-8AC6DD452ED5</gtr:id><gtr:title>The R1441C mutation alters the folding properties of the ROC domain of LRRK2.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd75dbe105014309cbdded985198a393"><gtr:id>bd75dbe105014309cbdded985198a393</gtr:id><gtr:otherNames>Li Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>2134C620CD1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18D7FDF8-7322-4843-A8DB-718D16F011FA</gtr:id><gtr:title>Beta-PrP form of human prion protein stimulates production of monoclonal antibodies to epitope 91-110 that recognise native PrPSc.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a01d25033815bed5d0d7bc3dc096d32c"><gtr:id>a01d25033815bed5d0d7bc3dc096d32c</gtr:id><gtr:otherNames>Khalili-Shirazi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>pKuURTmwiwD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>543F7841-4234-4060-A81C-2DC5D7F27765</gtr:id><gtr:title>Pharmacological chaperone for the structured domain of human prion protein.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47d5e240428d904766fabe26c08463fd"><gtr:id>47d5e240428d904766fabe26c08463fd</gtr:id><gtr:otherNames>Nicoll AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>mZBW3ttfBSj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42B645AC-093E-4FB6-A643-F74A1398AE5E</gtr:id><gtr:title>The cellular prion protein is preferentially expressed by CD4+ CD25+ Foxp3+ regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f2054f5020a7ad7e4cf404fcb230223"><gtr:id>5f2054f5020a7ad7e4cf404fcb230223</gtr:id><gtr:otherNames>Isaacs JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>ECF9A645A9A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD049AAB-AD14-4313-9168-1D4C5BD4E4BC</gtr:id><gtr:title>Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53740aa86cab452a475ba97e3f46e1b0"><gtr:id>53740aa86cab452a475ba97e3f46e1b0</gtr:id><gtr:otherNames>Cronier S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>XcefCYzbD2C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C04874CF-CA59-488C-9B97-1BDB2AA8BAD6</gtr:id><gtr:title>Disease-associated prion protein oligomers inhibit the 26S proteasome.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b2c9e84a2d8cce8f9ac2c9beec0c386"><gtr:id>0b2c9e84a2d8cce8f9ac2c9beec0c386</gtr:id><gtr:otherNames>Kristiansen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>Cn593F8ZtP4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B40DE744-4BF3-4A5D-ADAF-E4D299AE0034</gtr:id><gtr:title>Highly sensitive, quantitative cell-based assay for prions adsorbed to solid surfaces.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7b7e2fe78d5e2742820eea3aa14ddd"><gtr:id>5d7b7e2fe78d5e2742820eea3aa14ddd</gtr:id><gtr:otherNames>Edgeworth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>BopfMWcYMsz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88307177-BCB6-4F60-A52A-D5FAA2A346F3</gtr:id><gtr:title>A systematic investigation of production of synthetic prions from recombinant prion protein.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b2740857e0a6a774e56992f6a12381e"><gtr:id>7b2740857e0a6a774e56992f6a12381e</gtr:id><gtr:otherNames>Schmidt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56a8a7b87cd488.20450985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8906CE95-5CD0-4A58-BB28-9C265EB63CB5</gtr:id><gtr:title>The human prion protein residue 129 polymorphism lies within a cluster of epitopes for T cell recognition.</gtr:title><gtr:parentPublicationTitle>Journal of neuropathology and experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f2054f5020a7ad7e4cf404fcb230223"><gtr:id>5f2054f5020a7ad7e4cf404fcb230223</gtr:id><gtr:otherNames>Isaacs JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3069</gtr:issn><gtr:outcomeId>F3C96709776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73473E94-876E-4C08-9383-C0E79D6327D7</gtr:id><gtr:title>Conformational properties of beta-PrP.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15445b32afbe19ecababb3bb975097f8"><gtr:id>15445b32afbe19ecababb3bb975097f8</gtr:id><gtr:otherNames>Hosszu LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>WBxsYnF7raA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DDE7F99-050F-459D-8501-58A73305BDD2</gtr:id><gtr:title>Removal of the glycosylphosphatidylinositol anchor from PrP(Sc) by cathepsin D does not reduce prion infectivity.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>Np4vnPGqVJ6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4995D1F1-4D4A-4441-BC1A-04D1AF1970F8</gtr:id><gtr:title>Physical, chemical and kinetic factors affecting prion infectivity.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e107587b5118dadea420a7a7c6a23acc"><gtr:id>e107587b5118dadea420a7a7c6a23acc</gtr:id><gtr:otherNames>Properzi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>58c6a328653767.39423468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FC66AF6-1B54-44D5-B061-A5930990B67F</gtr:id><gtr:title>Variant Creutzfeldt-Jakob disease with extremely low lymphoreticular deposition of prion protein.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>54575d4b0922c2.49540072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6AB4634-198A-4F70-8B06-9A1F4E6943D4</gtr:id><gtr:title>The legs at odd angles (Loa) mutation in cytoplasmic dynein ameliorates mitochondrial function in SOD1G93A mouse model for motor neuron disease.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67850162a1b7fefe9245641a6e9ad020"><gtr:id>67850162a1b7fefe9245641a6e9ad020</gtr:id><gtr:otherNames>El-Kadi AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>d43XeokvdSy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80E10F66-4541-47C6-B77F-F9F3D3D2813C</gtr:id><gtr:title>Efficient dissemination of prions through preferential transmission to nearby cells.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43040ac71d856d0a4a990d656d83428d"><gtr:id>43040ac71d856d0a4a990d656d83428d</gtr:id><gtr:otherNames>Paquet S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>B42394297D8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB26DDCD-032D-46D6-BD50-8B65FB9FF2AF</gtr:id><gtr:title>Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b20fe581f807c3e4e12bea8541550d02"><gtr:id>b20fe581f807c3e4e12bea8541550d02</gtr:id><gtr:otherNames>Luk C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>58c6a328323cb2.54811009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2764F05E-ED13-4564-BEA4-84F08C1DB68E</gtr:id><gtr:title>A role of cellular prion protein in programming T-cell cytokine responses in disease.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c35e3d09ec2e2e40fe521134fc0b066"><gtr:id>5c35e3d09ec2e2e40fe521134fc0b066</gtr:id><gtr:otherNames>Ingram RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>092A8015FF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD6D22B4-07C7-4B4F-A5C1-4780DB3C93B2</gtr:id><gtr:title>A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e073b120372c44bd19d0a6219bb4623"><gtr:id>3e073b120372c44bd19d0a6219bb4623</gtr:id><gtr:otherNames>Tattum MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>AAHi1R6ofHz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2288533-F5BB-47EF-829D-FCE2D667FFEC</gtr:id><gtr:title>Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9ddd65d8294adde2619328d3384b1cd"><gtr:id>f9ddd65d8294adde2619328d3384b1cd</gtr:id><gtr:otherNames>Chia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>RyisFWeJoi7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D834FA80-39E6-4FF2-97DB-E5D1ED3A55BF</gtr:id><gtr:title>Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d35fcc5cee51bf10673b89f590a94d4a"><gtr:id>d35fcc5cee51bf10673b89f590a94d4a</gtr:id><gtr:otherNames>Jackson GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>54575d4ad61206.88891020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E053313C-16B7-4D7B-83FA-ED2163D54373</gtr:id><gtr:title>A standardized comparison of commercially available prion decontamination reagents using the Standard Steel-Binding Assay.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7b7e2fe78d5e2742820eea3aa14ddd"><gtr:id>5d7b7e2fe78d5e2742820eea3aa14ddd</gtr:id><gtr:otherNames>Edgeworth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>ex6HdshepEF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0BC5770-9AAB-44C1-B1FD-A1FF5D05973F</gtr:id><gtr:title>Folding kinetics of the human prion protein probed by temperature jump.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f2112888dab4fb3e6b612aa777ffe44"><gtr:id>1f2112888dab4fb3e6b612aa777ffe44</gtr:id><gtr:otherNames>Hart T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>qbdf3Fieoz7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CD449A6-1BA2-40E4-B0BB-8F3210A73EC6</gtr:id><gtr:title>Multiple forms of copper (II) co-ordination occur throughout the disordered N-terminal region of the prion protein at pH 7.4.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2b398fefefb405c70b3a85a98965243"><gtr:id>c2b398fefefb405c70b3a85a98965243</gtr:id><gtr:otherNames>Wells MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>sb4E3sSj6Yh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39443229-15AC-46E5-B1E4-7EA606EA8E97</gtr:id><gtr:title>Elongated oligomers assemble into mammalian PrP amyloid fibrils.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e073b120372c44bd19d0a6219bb4623"><gtr:id>3e073b120372c44bd19d0a6219bb4623</gtr:id><gtr:otherNames>Tattum MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>gPeTsfNUiw4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C16BCA6F-CAE6-41E6-B795-1689C03AC9D2</gtr:id><gtr:title>The H187R mutation of the human prion protein induces conversion of recombinant prion protein to the PrP(Sc)-like form.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15445b32afbe19ecababb3bb975097f8"><gtr:id>15445b32afbe19ecababb3bb975097f8</gtr:id><gtr:otherNames>Hosszu LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>SFw4tyqZu4V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9C0F800-CF43-468E-A151-E9BEF25DA677</gtr:id><gtr:title>Crystal structure of human prion protein bound to a therapeutic antibody.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02ad916747b020af716f1fe16ba777e9"><gtr:id>02ad916747b020af716f1fe16ba777e9</gtr:id><gtr:otherNames>Antonyuk SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>DjLBdasVLvw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D90DFC9-2AE2-47D0-BB37-DD2189013600</gtr:id><gtr:title>Blood test for variant Creutzfeldt-Jakob disease--reply.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d35fcc5cee51bf10673b89f590a94d4a"><gtr:id>d35fcc5cee51bf10673b89f590a94d4a</gtr:id><gtr:otherNames>Jackson GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>54575d4aa9b0e7.87259701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80BA22B1-695E-43D4-9177-7C238A2D0A6F</gtr:id><gtr:title>Spontaneous generation of mammalian prions.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7b7e2fe78d5e2742820eea3aa14ddd"><gtr:id>5d7b7e2fe78d5e2742820eea3aa14ddd</gtr:id><gtr:otherNames>Edgeworth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>A1gDazMLXG5</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U123170362</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>